1-15 of 15
Alan V. Boddy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Lucas Moreno, Lynley V. Marshall, Andrew D.J. Pearson, Bruce Morland, Martin Elliott, Quentin Campbell-Hewson, Guy Makin, Sarah E.R. Halford, Gary Acton, Philip Ross, Shamim Kazmi-Stokes, Victoria Lock, Ana Rodriguez, John F. Lyons, Alan V. Boddy, Melanie J. Griffin, Murray Yule, Darren Hargrave
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (2): 267–273.
https://doi.org/10.1158/1078-0432.CCR-14-1592
Published: 14 January 2015
View article titled, A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study
Open the PDF for A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study in another window
Includes: Supplementary data
Journal Articles

Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma

Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, Ghada Malik, Michael Cole, Ann K. Daly, Andrew D.J. Pearson, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 469–479.
https://doi.org/10.1158/1078-0432.CCR-12-2225
Published: 16 January 2013
View article titled, Adaptive Dosing Approaches to the Individualization of 13-<em>Cis</em>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma
Open the PDF for Adaptive Dosing Approaches to the Individualization of 13-<em>Cis</em>-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Ruth Plummer, Laura Vidal, Melanie Griffin, Mark Lesley, Johann de Bono, Sally Coulthard, Julieann Sludden, Lillian L. Siu, Eric X. Chen, Amit M. Oza, Gregory K. Reid, A. Robert McLeod, Jeffrey M. Besterman, Chooi Lee, Ian Judson, Hilary Calvert, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3177–3183.
https://doi.org/10.1158/1078-0432.CCR-08-2859
Published: 30 April 2009
View article titled, Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors in another window
Journal Articles

Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma

Rachel A. Daniel, Agata L. Rozanska, Huw D. Thomas, Evan A. Mulligan, Yvette Drew, Deborah J. Castelbuono, Zdenek Hostomsky, E. Ruth Plummer, Alan V. Boddy, Deborah A. Tweddle, Nicola J. Curtin, Steven C. Clifford
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (4): 1241–1249.
https://doi.org/10.1158/1078-0432.CCR-08-1095
Published: 19 February 2009
View article titled, Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma
Open the PDF for Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies

Ruth Plummer, Penella Woll, David Fyfe, Alan V. Boddy, Melanie Griffin, Paula Hewitt, James Carmichael, Fouad Namouni, Marvin Cohen, Mark Verrill
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8288–8294.
https://doi.org/10.1158/1078-0432.CCR-08-0471
Published: 15 December 2008
View article titled, A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies in another window
Journal Articles

Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group

Markus Joerger, Alwin D.R. Huitema, Dick J. Richel, Christian Dittrich, Nikolas Pavlidis, Evangelos Briasoulis, Jan B. Vermorken, Elena Strocchi, Andrea Martoni, Roberto Sorio, Henk P. Sleeboom, Miguel A. Izquierdo, Duncan I. Jodrell, Hilary Calvert, Alan V. Boddy, Harry Hollema, Regine Féty, Wjf J.F. Van der Vijgh, Georg Hempel, Etienne Chatelut, Mats Karlsson, Justin Wilkins, Brigitte Tranchand, Ad H.G.J. Schrijvers, Christian Twelves, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6410–6418.
https://doi.org/10.1158/1078-0432.CCR-07-0064
Published: 01 November 2007
View article titled, Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group
Open the PDF for Population Pharmacokinetics and Pharmacodynamics of Paclitaxel and Carboplatin in Ovarian Cancer Patients: A Study by the European Organization for Research and Treatment of Cancer-Pharmacology and Molecular Mechanisms Group and New Drug Development Group in another window
Journal Articles

Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia

Alan V. Boddy, Julieann Sludden, Melanie J. Griffin, Colin Garner, John Kendrick, Pritesh Mistry, Catherine Dutreix, David R. Newell, Stephen G. O'Brien
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (14): 4164–4169.
https://doi.org/10.1158/1078-0432.CCR-06-2179
Published: 18 July 2007
View article titled, Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia
Open the PDF for Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia in another window
Journal Articles

NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism

David Jamieson, Kerrie Wilson, Simon Pridgeon, Jane P. Margetts, Richard J. Edmondson, Hing Y. Leung, Richard Knox, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1584–1590.
https://doi.org/10.1158/1078-0432.CCR-06-1416
Published: 01 March 2007
View article titled, NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism
Open the PDF for NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 Activity and Expression in Bladder and Ovarian Cancer and Lower NRH:Quinone Oxidoreductase 2 Activity Associated with an NQO2 Exon 3 Single-Nucleotide Polymorphism in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

Alan V. Boddy, E. Ruth Plummer, Radha Todd, Julieann Sludden, Melanie Griffin, Lesley Robson, James Cassidy, Donald Bissett, Alberto Bernareggi, Mark W. Verrill, A. Hilary Calvert
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7834–7840.
https://doi.org/10.1158/1078-0432.CCR-05-0803
Published: 08 November 2005
View article titled, A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules
Open the PDF for A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules in another window
Journal Articles

Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study

Gareth J. Veal, Michael Cole, Julie Errington, Annie Parry, Juliet Hale, Andrew D.J. Pearson, Karen Howe, Julia C. Chisholm, Carol Beane, Bernadette Brennan, Fiona Waters, Adam Glaser, Sue Hemsworth, Heather McDowell, Yvonne Wright, Kathy Pritchard-Jones, Ross Pinkerton, Gail Jenner, James Nicholson, Ann M. Elsworth, Alan V. Boddy, UKCCSG Pharmacology Working Group
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5893–5899.
https://doi.org/10.1158/1078-0432.CCR-04-2546
Published: 22 August 2005
View article titled, Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study
Open the PDF for Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study in another window
Journal Articles

Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1

E. Ruth Plummer, Mark R. Middleton, Christopher Jones, Anna Olsen, Ian Hickson, Peter McHugh, Geoffrey P. Margison, Gail McGown, Mary Thorncroft, Amanda J. Watson, Alan V. Boddy, A. Hilary Calvert, Adrian L. Harris, David R. Newell, Nicola J. Curtin
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3402–3409.
https://doi.org/10.1158/1078-0432.CCR-04-2353
Published: 02 May 2005
View article titled, Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Open the PDF for Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes <em>O</em><sup>6</sup>-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1 in another window
Journal Articles

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma

S. Murray Yule, Lisa Price, Alex D. McMahon, Andrew D. J. Pearson, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 455–460.
https://doi.org/10.1158/1078-0432.CCR-0844-03
Published: 03 February 2004
View article titled, Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma
Open the PDF for Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma in another window
Journal Articles

Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy

Gareth J. Veal, Cinara Dias, Lisa Price, Annie Parry, Julie Errington, Juliet Hale, Andrew D. J. Pearson, Alan V. Boddy, David R. Newell, Michael J. Tilby
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2205–2212.
Published: 01 August 2001
View article titled, Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy
Open the PDF for Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy in another window
Journal Articles

Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines

Xiaohong Lu, Julie Errington, Victor J. Chen, Nicola J. Curtin, Alan V. Boddy, David R. Newell
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 271–277.
Published: 01 January 2001
View article titled, Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines
Open the PDF for Cellular ATP Depletion by LY309887 as a Predictor of Growth Inhibition in Human Tumor Cell Lines in another window
Journal Articles

Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days

Andy N. Hughes, Imran Rafi, Melanie J. Griffin, A. Hilary Calvert, David R. Newell, Joanne A. Calvete, Amanda Johnston, Neil Clendeninn, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 111–118.
Published: 01 January 1999
View article titled, Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days
Open the PDF for Phase I Studies with the Nonclassical Antifolate Nolatrexed Dihydrochloride (AG337, THYMITAQ) Administered Orally for 5 Days in another window